The EPS miss and accelerating cash burn are the primary negatives, partially offset by TONMYA's early commercial traction. Watch for the 10-Q filing (expected ~May 11) for full financials and any guidance on TONMYA prescription trends and payer coverage expansion. The ATM dilution pattern is a persistent overhang.
Price Chart
Executive Summary
Tonix Pharmaceuticals reported Q1 2026 revenue of $6.9M, up 183% YoY from $2.4M, driven by the TONMYA launch ($3.7M in its first full quarter). However, the net loss widened to $40.2M from $16.8M YoY as operating expenses surged to $48.4M (R&D + SG&A) to support commercialization. EPS of -$2.93 missed consensus of -$2.54 by 15.4%. Cash burn accelerated to $42.3M in operating cash flow, and the company raised $22.6M post-quarter via ATM to extend runway into early Q2 2027.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue $6.9M vs $2.4M YoY (+183%), including $3.7M from TONMYA (launched Nov 2025)
- Net loss widened to $40.2M from $16.8M YoY; EPS -$2.93 missed consensus of -$2.54 (-15.4%)
- Operating expenses surged to $48.4M from $18.5M YoY, driven by $28.6M SG&A (sales/marketing for TONMYA) and $18.2M R&D
- Cash and equivalents $185.5M at March 31, 2026, down from $207.6M a year ago; net cash used in operations $42.3M vs $16.6M YoY
- Post-quarter raised $22.6M via ATM; cash runway extended into early Q2 2027
- TONMYA metrics: 2,145 prescribers, 3,588 patients initiated, ~5,400 prescriptions filled in Q1; GPO deal covers ~35M commercial lives
- Shares outstanding rose to 15.9M as of May 8, 2026, from 5.9M a year ago (dilution from ATM and prior equity raises)
Financial Impact
Net loss of $40.2M on $6.9M revenue; EPS miss of 15.4% vs consensus; cash burn rate doubled YoY
Risk Factors
- Cash burn rate doubled YoY to $42.3M/quarter; runway only into early Q2 2027 despite $22.6M ATM raise
- Dilution from ATM and equity raises: shares outstanding tripled YoY to 15.9M
- TONMYA revenue still small ($3.7M) relative to $48.4M operating expenses; path to profitability unclear
- Pipeline programs (TNX-4800, TNX-102 SL) are early-stage with no near-term revenue catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001999371-26-010487 |
| Document: tnxp-8k_051126.htm | 0001999371-26-010487 |
| Document: 0001999371-26-010487-index-headers.html | 0001999371-26-010487 |
| Document: 0001999371-26-010487-index.html | 0001999371-26-010487 |
| Document: 0001999371-26-010487.txt | 0001999371-26-010487 |
| 8-K Data (Synthetic) | 0001999371-26-010487 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers